Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
NTLA News
In late October 2025, Intellia Therapeutics announced that the FDA had placed a clinical hold on its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for the gene-editi...
Analysts are intrested in these 5 stocks: ( (DASH) ), ( (MSFT) ), ( (NTLA) ), ( (UPWK) ) and ( (QRVO) ). Here is a breakdown of their recent ratings and the rat...
BofA analyst Alec Stranahan downgraded Intellia Therapeutics (NTLA) to Neutral from Buy with a price target of $14, down from $30. Intellia’s Phase 3 trial paus...
Analyst ratings
58%
of 26 ratingsMore NTLA News
Wedbush analyst David Nierengarten lowered the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Neutral rating on the shares. The...
Intellia Therapeutics Inc (NASDAQ:NTLA) shares are tumbling in after-hours trading on Wednesday after the company announced the U.S. Food and Drug Administratio...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
News of Intellia Therapeutics halting its Phase 3 trials because of a serious liver safety event is getting a lot of attention among investors in CRISPR Therape...
20:44 EDT Cathie Wood’s ARK Investment buys 479.4K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time,...
J.P. Morgan analyst Brian Cheng has maintained their neutral stance on NTLA stock, giving a Hold rating today. Elevate Your Investing Strategy: Take advantage o...
Alec Stranahan, an analyst from Bank of America Securities, reiterated the Buy rating on Intellia Therapeutics. The associated price target was lowered to $30.0...